E.R. Costs for Mentally Ill Soar, and Hospitals Seek Better Way New York Times By JULIE CRESWELL December 25, 2013 As darkness fell on a Friday evening over downtown Raleigh, N.C., Michael Lyons, a paramedic supervisor for Wake County Emergency Medical Services, slowly approached the tall, lanky man who was swaying back and forth in […]
In the last post [almost inevitable…] proposing that the CAFE study was cloned from the CATIE study without considering the different populations being studied, I mentioned the many similarities between them. Well here’s another similarity: In spite of their age, neither study had results posted on clinicaltrials.gov… Despite Law, Fewer Than One In Eight Completed […]
Will the U review or whitewash a research subject’s death? Star Tribune by MATT LAMKIN December 18, 2013 As scholars of medical ethics and proud alumni of the University of Minnesota, we have been pained by the cloud that has hung over our alma mater in the decade since Dan Markingson killed himself while enrolled […]
Moving from left to right, first there was TMAP [1998], the PHARMA scheme originating in Texas that had seventeen States paying top dollar for psychotropic drugs instead of using the equivalent generics – finally busted by Allen Jones blowing the whistle. It was followed by STAR*D [2001], the $35 M sequencing study of antidepressants that […]
I’ve underlined everything new in this article as a reading aid: A New Focus on Depression New York Times By RICHARD A. FRIEDMAN, M.D. December 23, 2013 When will we ever get depression under control? Of all the major illnesses, mental or physical, depression has been one of the toughest to subdue. Despite the ubiquity […]
hat tip to Uri …
Happy Holidays!
Up front, my apologies for being redundant. This first Pharmalot post is from February [on the right track…]. I just thought Ed’s post today needed the background to make sense of this story: A Tough Push For Clinical Trial Disclosure In Europe Pharmalot By Ed Silverman February 4th, 2013 As the debate over clinical trial […]
2003 was a long time ago for me. It was the year I retired from practice, sold my house in Atlanta, and moved to the mountains. It was also the year Jon Jureidini first wrote the JAACAP about the Paxil® Study 329 article, but I didn’t know about that then. I did, however, know about […]
I report here only the conclusions from this article in the BMJ. I didn’t purloin the whole article, not because of copyright restrictions, but to support subscribing to this journal. It’s my only paid subscription, even though I have free emeritus faculty access. Editor Fiona Godlee has emerged along with Marcia Angell as the editors […]